Skip to main content

Advertisement

Articles

Page 1 of 16

  1. Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer’s disease (AD...

    Authors: Marta Marquié, Sergi Valero, Miguel Castilla-Marti, Joan Martínez, Octavio Rodríguez-Gómez, Ángela Sanabria, Juan Pablo Tartari, Gemma C. Monté-Rubio, Oscar Sotolongo-Grau, Montserrat Alegret, Alba Pérez-Cordón, Natalia Roberto, Itziar de Rojas, Sonia Moreno-Grau, Laura Montrreal, Isabel Hernández…

    Citation: Alzheimer's Research & Therapy 2020 12:37

    Content type: Research

    Published on:

  2. β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...

    Authors: James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao-Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins and Colin L. Masters

    Citation: Alzheimer's Research & Therapy 2020 12:36

    Content type: Research

    Published on:

  4. TDP-43 type C is one of the pathological forms of frontotemporal lobar degeneration (FTLD) and mainly associated clinically with the semantic variant of primary progressive aphasia (svPPA). We aimed to define ...

    Authors: Martina Bocchetta, Maria del Mar Iglesias Espinosa, Tammaryn Lashley, Jason D. Warren and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2020 12:34

    Content type: Research

    Published on:

  5. Pathological analysis of brain tissue from animals and humans with a history of traumatic brain injury (TBI) suggests that TBI could be one of the risk factors facilitating onset of dementia with possible Alzh...

    Authors: Mingfei Li, Joel Reisman, Benjamin Morris-Eppolito, Shirley X. Qian, Lewis E. Kazis, Benjamin Wolozin, Lee E. Goldstein and Weiming Xia

    Citation: Alzheimer's Research & Therapy 2020 12:33

    Content type: Research

    Published on:

  6. After the publication of this article [1], we became aware that there were errors in Figs. 4 and 31.

    Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

    Citation: Alzheimer's Research & Therapy 2020 12:32

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2020 12:13

  7. Abnormal beta-amyloid (Aβ) is associated with deleterious changes in central cholinergic tone in the very early stages of Alzheimer’s disease (AD), which may be unmasked by a cholinergic antagonist (J Prev Alz...

    Authors: Jessica Alber, Paul Maruff, Cláudia Y. Santos, Brian R. Ott, Stephen P. Salloway, Don C. Yoo, Richard B. Noto, Louisa I. Thompson, Danielle Goldfarb, Edmund Arthur, Alex Song and Peter J. Snyder

    Citation: Alzheimer's Research & Therapy 2020 12:31

    Content type: Research

    Published on:

  8. As research in treatments for neurocognitive diseases progresses, there is an increasing need to identify cognitive decline in the earliest stages of disease for initiation of treatment in addition to determin...

    Authors: Emma Borland, Erik Stomrud, Danielle van Westen, Oskar Hansson and Sebastian Palmqvist

    Citation: Alzheimer's Research & Therapy 2020 12:30

    Content type: Research

    Published on:

  9. The pathological hallmarks of Alzheimer’s disease (AD) involve alterations in the expression of numerous genes associated with transcriptional levels, which are determined by chromatin accessibility. Here, the...

    Authors: Yaqi Wang, Xiaomin Zhang, Qiao Song, Yuli Hou, Jing Liu, Yu Sun and Peichang Wang

    Citation: Alzheimer's Research & Therapy 2020 12:29

    Content type: Research

    Published on:

  10. Potential moderators such as exercise intensity or apolipoprotein-E4 (ApoE4) carriership may determine the magnitude of exercise effects on physical and cognitive functions in patients with dementia (PwD). We ...

    Authors: L. M. J. Sanders, T. Hortobágyi, E. G. A. Karssemeijer, E. A. Van der Zee, E. J. A. Scherder and M. J. G. van Heuvelen

    Citation: Alzheimer's Research & Therapy 2020 12:28

    Content type: Research

    Published on:

  11. Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS. When disease-modifying agents ...

    Authors: David Mengel, Wen Liu, Robert J. Glynn, Dennis J. Selkoe, Andre Strydom, Florence Lai, H. Diana Rosas, Amy Torres, Vasiliki Patsiogiannis, Brian Skotko and Dominic M. Walsh

    Citation: Alzheimer's Research & Therapy 2020 12:27

    Content type: Research

    Published on:

  12. Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate betwe...

    Authors: Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz, Philippe Marin, François Becher, Chihiro Sato, Audrey Gabelle and Sylvain Lehmann

    Citation: Alzheimer's Research & Therapy 2020 12:26

    Content type: Research

    Published on:

  13. Computerized neuropsychological tests for early detection of Alzheimer’s disease (AD) have attracted increasing interest. Memory for faces and proper names is a complex task because its association is arbitrar...

    Authors: Montserrat Alegret, Nathalia Muñoz, Natalia Roberto, Dorene M. Rentz, Sergi Valero, Silvia Gil, Marta Marquié, Isabel Hernández, Catalina Riveros, Angela Sanabria, Alba Perez-Cordon, Ana Espinosa, Gemma Ortega, Ana Mauleón, Carla Abdelnour, Maitee Rosende-Roca…

    Citation: Alzheimer's Research & Therapy 2020 12:25

    Content type: Research

    Published on:

  14. The functional autonomy assessment is essential to manage patients with a neurodegenerative disease, but its evaluation is not always possible during a consultation. To optimize ambulatory autonomy assessment,...

    Authors: Virginie Dauphinot, Nawèle Boublay, Claire Moutet, Sarah Achi, Anthony Bathsavanis and Pierre Krolak-Salmon

    Citation: Alzheimer's Research & Therapy 2020 12:24

    Content type: Research

    Published on:

  16. The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer...

    Authors: Sanka Amadoru, Vincent Doré, Catriona A. McLean, Fairlie Hinton, Claire E. Shepherd, Glenda M. Halliday, Cristian E. Leyton, Paul A. Yates, John R. Hodges, Colin L. Masters, Victor L. Villemagne and Christopher C. Rowe

    Citation: Alzheimer's Research & Therapy 2020 12:22

    Content type: Research

    Published on:

  17. Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical d...

    Authors: Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo and Susan M. Catalano

    Citation: Alzheimer's Research & Therapy 2020 12:21

    Content type: Review

    Published on:

  18. Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold s...

    Authors: Pawel Obrocki, Ayesha Khatun, Deborah Ness, Konstantin Senkevich, Jörg Hanrieder, Federica Capraro, Niklas Mattsson, Ulf Andreasson, Erik Portelius, Nicholas J. Ashton, Kaj Blennow, Michael Schöll, Ross W. Paterson, Jonathan M. Schott and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2020 12:20

    Content type: Review

    Published on:

  19. The human APOE gene, which codes for apolipoprotein E (apoE), has three major polymorphic alleles: ε2, ε3, and ε4 that give rise to amino acid substitutions. APOE-ε4 is a strong risk factor of sporadic Alzheimer’...

    Authors: K. Minta, G. Brinkmalm, S. Janelidze, S. Sjödin, E. Portelius, E. Stomrud, H. Zetterberg, K. Blennow, O. Hansson and U. Andreasson

    Citation: Alzheimer's Research & Therapy 2020 12:19

    Content type: Research

    Published on:

  20. Biomarkers are increasingly employed for effective research into neurodegenerative diseases. They have become essential for reaching an accurate clinical diagnosis, monitoring disease, and refining entry crite...

    Authors: Ayesha Khatun, Ross W. Paterson and Michael Schöll

    Citation: Alzheimer's Research & Therapy 2020 12:18

    Content type: Review

    Published on:

  22. Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD...

    Authors: Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin and Angelica Quartino

    Citation: Alzheimer's Research & Therapy 2020 12:16

    Content type: Research

    Published on:

  23. Metabotropic glutamate subtype 5 receptors (mGluR5) modulate synaptic transmission and may constitute an important therapeutic target in Alzheimer’s disease (AD) by mediating the synaptotoxic action of amyloid...

    Authors: Adam P. Mecca, Julia W. McDonald, Hannah R. Michalak, Tyler A. Godek, Joanna E. Harris, Erika A. Pugh, Emily C. Kemp, Ming-Kai Chen, Arash Salardini, Nabeel B. Nabulsi, Keunpoong Lim, Yiyun Huang, Richard E. Carson, Stephen M. Strittmatter and Christopher H. van Dyck

    Citation: Alzheimer's Research & Therapy 2020 12:15

    Content type: Research

    Published on:

  24. Although structural and functional changes of the striatum and hippocampus are present in familial Alzheimer’s disease, little is known about the effects of specific gene mutation or disease progression on the...

    Authors: Meina Quan, Tan Zhao, Yi Tang, Ping Luo, Wei Wang, Qi Qin, Tingting Li, Qigeng Wang, Jiliang Fang and Jianping Jia

    Citation: Alzheimer's Research & Therapy 2020 12:14

    Content type: Research

    Published on:

  25. Mounting evidence points to a crucial role of amyloid-β (Aβ) in the pathophysiology of Alzheimer’s disease (AD), a disorder in which brain glucose hypometabolism, downregulation of central elements of phosphor...

    Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

    Citation: Alzheimer's Research & Therapy 2020 12:13

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:32

  26. Pyroglutamate-3 Aβ (pGlu-3 Aβ) is an N-terminally truncated and post-translationally modified Aβ species found in Alzheimer’s disease (AD) brain. Its increased peptide aggregation propensity and toxicity make ...

    Authors: Helen Crehan, Bin Liu, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Kevin X. Le, Barbara J. Caldarone, Jeffrey L. Frost, Thore Hettmann, Birgit Hutter-Paier, Brian O’Nuallain, Mi-Ae Park, Marcelo F. DiCarli, Inge Lues, Stephan Schilling and Cynthia A. Lemere

    Citation: Alzheimer's Research & Therapy 2020 12:12

    Content type: Research

    Published on:

  27. Evidence from previous studies suggests that bilingualism contributes to cognitive reserve because bilinguals manifest the first symptoms of Alzheimer’s disease (AD) up to 5 years later than monolinguals. Othe...

    Authors: Víctor Costumero, Lidon Marin-Marin, Marco Calabria, Vicente Belloch, Joaquín Escudero, Miguel Baquero, Mireia Hernandez, Juan Ruiz de Miras, Albert Costa, Maria-Antònia Parcet and César Ávila

    Citation: Alzheimer's Research & Therapy 2020 12:11

    Content type: Research

    Published on:

  28. To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we inv...

    Authors: Jolien F. Leijenaar, Geert Jan Groeneveld, Erica S. Klaassen, Anna E. Leeuwis, Philip Scheltens, Henry C. Weinstein, Joop M. A. van Gerven, Frederik Barkhof, Wiesje M. van der Flier and Niels D. Prins

    Citation: Alzheimer's Research & Therapy 2020 12:10

    Content type: Research

    Published on:

  29. Mounting evidence links poor sleep quality with a higher risk of late-life dementia. However, the structural and cognitive correlates of insomnia are still not well understood. The study aims were to character...

    Authors: Oriol Grau-Rivera, Grégory Operto, Carles Falcón, Gonzalo Sánchez-Benavides, Raffaele Cacciaglia, Anna Brugulat-Serrat, Nina Gramunt, Gemma Salvadó, Marc Suárez-Calvet, Carolina Minguillon, Álex Iranzo, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2020 12:4

    Content type: Research

    Published on:

  30. Fluctuations are one of the core clinical features characterizing dementia with Lewy bodies (DLB). They represent a determining factor for its diagnosis and strongly impact the quality of life of patients and ...

    Authors: Eléna Chabran, Vincent Noblet, Paulo Loureiro de Sousa, Catherine Demuynck, Nathalie Philippi, Catherine Mutter, Pierre Anthony, Catherine Martin-Hunyadi, Benjamin Cretin and Frédéric Blanc

    Citation: Alzheimer's Research & Therapy 2020 12:9

    Content type: Research

    Published on:

  31. Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology...

    Authors: Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins…

    Citation: Alzheimer's Research & Therapy 2020 12:8

    Content type: Research

    Published on:

  32. Pathological processes contributing to Alzheimer’s disease begin decades prior to the onset of clinical symptoms. There is significant variation in cognitive changes in the presence of pathology, functional co...

    Authors: Chemin Lin, Maria Ly, Helmet T. Karim, Wenjing Wei, Beth E. Snitz, William E. Klunk and Howard J. Aizenstein

    Citation: Alzheimer's Research & Therapy 2020 12:7

    Content type: Research

    Published on:

  33. Although amyloid PET of typical Alzheimer’s disease (AD) shows diffuse ß-amyloid (Aß) deposition, some patients show focal deposition. The clinical significance of this focal Aß is not well understood. We exam...

    Authors: Si Eun Kim, Byungju Lee, Seongbeom Park, Soo Hyun Cho, Seung Joo Kim, Yeshin Kim, Hyemin Jang, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Na Yeon Jung, Bora Yoon, Jae-Won Jang, Jin Yong Hong, Jihye Hwang…

    Citation: Alzheimer's Research & Therapy 2020 12:6

    Content type: Research

    Published on:

  34. Alzheimer's disease (AD) is frequently accompanied by sleep impairment, which can induce AD-related neurodegeneration. We herein investigated the sleep architecture, cognition, and cerebrospinal fluid (CSF) bi...

    Authors: Claudio Liguori, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Nicola Biagio Mercuri and Alessandra Di Pucchio

    Citation: Alzheimer's Research & Therapy 2020 12:5

    Content type: Research

    Published on:

  35. Plasma and cerebrospinal fluid levels of neurofilament light (NfL), a marker of axonal degeneration, have previously been reported to be raised in patients with clinically diagnosed Alzheimer’s disease (AD). A...

    Authors: Peter Parbo, Lasse Stensvig Madsen, Rola Ismail, Henrik Zetterberg, Kaj Blennow, Simon F. Eskildsen, Thomas Vorup-Jensen and David J. Brooks

    Citation: Alzheimer's Research & Therapy 2020 12:3

    Content type: Research

    Published on:

  36. In neurodegenerative dementias (NDs) such as prion disease, Alzheimer’s disease (AD), and frontotemporal lobar degeneration (FTLD), protein misfolding leads to the tissue deposition of protein aggregates which...

    Authors: Samir Abu-Rumeileh, Petra Steinacker, Barbara Polischi, Angela Mammana, Anna Bartoletti-Stella, Patrick Oeckl, Simone Baiardi, Corrado Zenesini, André Huss, Pietro Cortelli, Sabina Capellari, Markus Otto and Piero Parchi

    Citation: Alzheimer's Research & Therapy 2019 12:2

    Content type: Research

    Published on:

  37. Insulin impairment and inflammation are two features common to type 2 diabetes and Alzheimer’s disease; however, the molecular and signaling interactions underlying this relationship are not well understood. M...

    Authors: Maria Elizabeth De Sousa Rodrigues, Madelyn C. Houser, Douglas I. Walker, Dean P. Jones, Jianjun Chang, Christopher J. Barnum and Malú G. Tansey

    Citation: Alzheimer's Research & Therapy 2019 12:1

    Content type: Research

    Published on:

  38. The application of advanced sequencing technologies and improved mass-spectrometry platforms revealed significant changes in gene expression and lipids in Alzheimer’s disease (AD) brain. The results so far hav...

    Authors: Iliya Lefterov, Cody M. Wolfe, Nicholas F. Fitz, Kyong Nyon Nam, Florent Letronne, Richard J. Biedrzycki, Julia Kofler, Xianlin Han, Jianing Wang, Jonathan Schug and Radosveta Koldamova

    Citation: Alzheimer's Research & Therapy 2019 11:113

    Content type: Research

    Published on:

  39. Growing evidence suggests a role of occupation in the emergence and manifestation of dementia. Occupations are often defined by complexity level, although working environments and activities differ in several ...

    Authors: A. C. van Loenhoud, C. de Boer, K. Wols, Y. A. Pijnenburg, A. W. Lemstra, F. H. Bouwman, N. D. Prins, P. Scheltens, R. Ossenkoppele and W. M. van der Flier

    Citation: Alzheimer's Research & Therapy 2019 11:112

    Content type: Research

    Published on:

  40. Due to the high cost and high failure rate of ascertaining amyloid positron emission tomography positivity (PET+) in patients with earlier stage Alzheimer’s disease (AD), an effective pre-screening tool for am...

    Authors: Szu-Ying Lin, Kun-Ju Lin, Po-Chen Lin, Chin-Chang Huang, Chiung-Chih Chang, Yi-Chung Lee, Ing-Tsung Hsiao, Tzu-Chen Yen, Wen-Sheng Huang, Bang-Hung Yang and Pei-Ning Wang

    Citation: Alzheimer's Research & Therapy 2019 11:111

    Content type: Research

    Published on:

  41. The persistence of adult hippocampal neurogenesis (AHN) is sharply decreased in Alzheimer’s disease (AD). The neuropathologies of AD include the presence of amyloid-β deposition in plaques, tau hyperphosphoryl...

    Authors: Jaewoo Shin, Chanho Kong, Jihyeon Lee, Bo Young Choi, Jiyeon Sim, Chin Su Koh, Minkyung Park, Young Cheol Na, Sang Won Suh, Won Seok Chang and Jin Woo Chang

    Citation: Alzheimer's Research & Therapy 2019 11:110

    Content type: Research

    Published on:

  42. We examined interactive effects of sex, diagnosis, and cerebrospinal fluid (CSF) amyloid beta/phosphorylated tau ratio (Aβ/P-tau) on verbal memory and hippocampal volumes.

    Authors: Jessica Z. K. Caldwell, Jeffrey L. Cummings, Sarah J. Banks, Sebastian Palmqvist and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2019 11:109

    Content type: Research

    Published on:

  43. Cortical and subcortical cognitive impairments are usually found in dementia with Lewy bodies (DLB). Roughly, they comprise visuo-constructive/executive function and attention/processing speed impairments, whe...

    Authors: Anne Botzung, Nathalie Philippi, Vincent Noblet, Paulo Loureiro de Sousa and Frédéric Blanc

    Citation: Alzheimer's Research & Therapy 2019 11:108

    Content type: Research

    Published on:

  44. Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive ...

    Authors: Hayk Davtyan, Armine Hovakimyan, Sepideh Kiani Shabestari, Tatevik Antonyan, Morgan A. Coburn, Karen Zagorski, Gor Chailyan, Irina Petrushina, Olga Svystun, Emma Danhash, Nikolai Petrovsky, David H. Cribbs, Michael G. Agadjanyan, Mathew Blurton-Jones and Anahit Ghochikyan

    Citation: Alzheimer's Research & Therapy 2019 11:107

    Content type: Research

    Published on:

  45. Brain amyloid deposition is one of the main pathological characteristics of Alzheimer’s disease (AD). Soluble oligomers formed during the process that causes β-amyloid (Aβ) to aggregate into plaques are consid...

    Authors: Jian-Xiang Zhang, Yi-Hui Lai, Pan-Ying Mi, Xue-Ling Dai, Ran Zhang, Zhan-Jun Zhang, Shu-Juan Zhang, Xi-Wen Zhang, Xi-Yan Zhang, Bing-Yu Yang, Dong-Mei Cui, Chen Zhang, Chang-Qi Zhao and Fei Dou

    Citation: Alzheimer's Research & Therapy 2019 11:106

    Content type: Research

    Published on:

  46. Increased CSF levels of a number of synaptic markers have been reported in Alzheimer’s disease (AD), but little is known about their concentrations in frontotemporal dementia (FTD). We investigated this in thr...

    Authors: Mica T. M. Clarke, Ann Brinkmalm, Martha S. Foiani, Ione O. C. Woollacott, Carolin Heller, Amanda Heslegrave, Ashvini Keshavan, Nick C. Fox, Jonathan M. Schott, Jason D. Warren, Kaj Blennow, Henrik Zetterberg and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2019 11:105

    Content type: Research

    Published on:

  47. The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-be...

    Authors: Daria Bortolotti, Valentina Gentili, Antonella Rotola, Elisabetta Caselli and Roberta Rizzo

    Citation: Alzheimer's Research & Therapy 2019 11:104

    Content type: Research

    Published on:

  48. Since both APOE and ABCA7 protein expression may independently reduce neuritic plaque burden and reorganize fibrillar amyloid burden-mediated disruption of functional connectivity in the default mode network, we ...

    Authors: Ya-Ting Chang, Shih-Wei Hsu, Shu-Hua Huang, Chi-Wei Huang, Wen-Neng Chang, Chia-Yi Lien, Jun-Jun Lee, Chen-Chang Lee and Chiung-Chih Chang

    Citation: Alzheimer's Research & Therapy 2019 11:103

    Content type: Research

    Published on:

  49. EphA4 is a receptor of the ephrin system regulating spine morphology and plasticity in the brain. These processes are pivotal in the pathophysiology of Alzheimer’s disease (AD), characterized by synapse dysfun...

    Authors: Lindsay Poppe, Laura Rué, Mieke Timmers, Annette Lenaerts, Annet Storm, Zsuzsanna Callaerts-Vegh, Gilles Courtand, Antina de Boer, Silke Smolders, Philip Van Damme, Ludo Van Den Bosch, Rudi D’Hooge, Bart De Strooper, Wim Robberecht and Robin Lemmens

    Citation: Alzheimer's Research & Therapy 2019 11:102

    Content type: Research

    Published on:

  50. We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR...

    Authors: Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura and Rachelle Doody

    Citation: Alzheimer's Research & Therapy 2019 11:101

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193